PKPD modelling of the relationship between testosterone and PSA

Snelder N., Drenth H., Bergmann K., Wood N., Hibberd M. and Scott G., PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin. What is the optimal testosterone level?, PAGE.(2015) [Link to publication]

Read More

Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis

Berkhout J., Stone J.A., Verhamme K.M., Stricker B.H., Sturkenboom M.C., Danhof M. and Post T.M., Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis, CPT Pharmacometrics Syst Pharmacol., 4(9): 516-526. doi: 510.1002/psp1004.12006. Epub 12015 Aug 12022., 2015. [Link to publication]

Read More

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations

Brochot A., Kakuda T.N., Van De Casteele T., Opsomer M., Tomaka F.L., Vermeulen A. and Vis P., Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged >/=3 to <12 Years, CPT Pharmacometrics Syst Pharmacol., 4(7): 406-414. doi: 410.1002/psp1004.1044. Epub 2015 Jun 1019., 2015. [Link to publication]

Read More

Dose Selection of Antithrombin (Recombinant)

Paidas M.J., Frieling J., de Jongh J., Drenth H.J. and Streisand J., Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149], Obstet Gynecol., 125(Suppl 1): 52S., 2015. [Link to publication]

Read More